Skip to content

A Study for the Behavior of Ingested Test Products in Blood

A Study for the Behavior of Ingested Test Products in Blood - A Study for the Behavior of Ingested Test Products in Blood

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000009383
Enrollment
10
Registered
2012-11-22
Start date
2012-11-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Improvement of dietary habit

Interventions

Fish oil product A 30 pills &gt
Washout period(6 days) Fish oil product B30 pills &gt
Washout period (6 days) Placebo products 30 pills Fish oil product B30 pills &gt
Washout period(6 days) Placebo product 30 pills &gt
Washout period (6 days) Fish oil product A 30 pills Placebo product 30 pills &gt
Washout period(6 days) Fish oil product A 30 pills &gt
Washout period (6 days) Fish oil product B 30 pills

Sponsors

Division of Bioscience and Biotechnology for Future Bioindustries, Graduate School of Agricultural Science, Tohoku University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: *Healthy Japanese males aged 20-30 years *Individuals whose BMI whose BMI is 18.5-25 *Individuals who are non-smoker *Individuals who don't continually take OTC drug (including herb medicine), food with health claims (food for specified health use), health food, and supplement *Individuals whose dietary habit is stable *Individuals who are able to abstain from eating from 10 hours prior to blood drawing period to the end of observation *Individuals judged appropriate for the study by the principal investigator

Exclusion criteria

Exclusion criteria: *Individuals using medical products *Individuals who are smoker *Individuals with serious serious anemia. *Individuals who are sensitive to medical products and cosmetics *Individuals who have anamnesis or history of present illness of cardiovascular disease, nephritic disorder, hepatic inflammation, or pancreatitis *Individuals whose observed data of AST, ALT and gamma-GT are over 2.5 times of standard value *Individuals who participated in other clinical studies in the past 3 months *Individuals judged inappropriate for the study by the principal investigator

Design outcomes

Secondary

MeasureTime frame
Blood pressure determination Pulse determination Weight determination Physician's history taking

Primary

MeasureTime frame
Serum lipid concentration

Countries

Japan

Contacts

Public ContactTES Holding Co., Ltd.

TES Holding Co., Ltd. Department of Clinical Trial

info@tes-h.co.jp03-6801-8480

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026